Experimental pharmacology of hirunorm: A novel synthetic peptide thrombin inhibitor

Thrombosis and Haemostasis

Volumn 76, Issue 3, 1996, Pages 384-392

  Cirillo, Rocco ^a,c   Lippi, Annalisa ^a   Subissi, Alessandro ^a   Agnelli, Giancarlo ^b   Criscuoli, Marco ^a  

^a Laboratori Guldotti   (Italy)

^b UNIVERSITY OF PERUGIA   (Italy)

^c Menarini Ricerche SpA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICOAGULANT AGENT; HIRUDIN; HIRULOG; HIRUNORM; HYDROLASE; PLASMIN; SYNTHETIC PEPTIDE; THROMBIN; THROMBIN INHIBITOR; TISSUE PLASMINOGEN ACTIVATOR; TRYPSIN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTERY THROMBOSIS; ARTICLE; BLEEDING TIME; BLOOD CLOTTING TIME; CAVA VEIN; CONTROLLED STUDY; CORONARY ARTERY THROMBOSIS; DRUG POTENCY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN CELL; HYDROLYSIS; INTRAVENOUS DRUG ADMINISTRATION; MALE; MESENTERY BLOOD VESSEL; NONHUMAN; PERCUTANEOUS TRANSLUMINAL ANGIOPLASTY; PLASMA; PRIORITY JOURNAL; RABBIT; RAT; SUBCUTANEOUS DRUG ADMINISTRATION; VEIN LIGATION; VEIN THROMBOSIS;

EID: 0029829854     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-0038-1650588     Document Type: Article

References (32)

1. Cannon CP, McCabe CH, Henry TD, Schweiger MJ, Gibson RS, Mueller HS, Becker RC, Kleiman NS, Haugland JM, Anderson JL, Sharaf BL, Edwards SJ, Rogers WJ, Williams DO, Braunwald E. A pilot trial of recombinant desulfatohirudin compared with heparin in conjunction with tissue type plasminogen activator and aspirin for acute myocardial infarction: results of the Thrombolysis In Myocardial Infarction (TIMI) 5 trial. J Am Coll Cardiol 1994; 23: 993-1003.
2. Eriksson BI, Kalebo P, Ekman S, Kerry R, Baur M. Effective prevention of thromboembolic complications after total hip replacement with three different doses of recombinant hirudin, CGP 39393 (Revasc®), Ciba, compared to unfractioned heparin. Circulation 1994; 90: 1-569 (abstract n° 3066).
3. Ginsberg JS, Nurmohamed MT, Gent M, Mackinnon B, Sicurella J, Brilledwards P, Levine MN, Panju AA, Powers P, Stevens P, Turpie AGO, Weitz J, Buller HR, Tencate JW, Neemeh J, Adelman B, Fox I, Maraganore J, Hirsh J. Use of hirulog in the prevention of venous thrombosis after major hip or knee surgery. Circulation 1994; 90: 2385-9.
4. Topol EJ, Fuster V, Harrington RA, Califf RM, Kleiman NS, Kereiakes DJ, Cohen M, Chapekis A, Gold HK, Tannenbaum MA, Rao AK, Debowey D, Schwanz D, Henis M, Chesebro J. Recombinant hirudin for unstable angina pectoris. A multicenter, randomized angiographie trial. Circulation 1994; 89: 1557-66.
5. Theroux P, Perez-Villa F, Waters D, Lesperance J, Shabani F, Bonan R. Randomized double-blind comparison of two doses of hirulog-1 with heparin as adjunctive therapy to streptokinase to promote early patency of the infarct-related artery in acute myocardial infarction. Circulation 1995; 91: 2132-9.
6. Maraganore JM, Bourdon P, Jablonski J, Ramachandran KL, Fenton JW. Design and characterization of hirulog: a novel class of bivalent peptide inhibitors of thrombin. Biochemistry 1990; 29: 7095-101.
7. Di Maio J, Gibbs B, Lefebvre J, Konishi Y, Munn D, Yi Yue S. Synthesis of a homologous series of ketomethylene arginyl pseudodipeptides and application to low molecular weight hirudin-like thrombin inhibitors. J Med Chem 1992; 35: 3331-41.
8. Thurieau C, Guyard C, Simonet S, Verbeuren TJ, Fauchère JL. Synthesis of a new bivalent hirudin analog (hirufos), which includes a stable 4'-phosphono-L-phenylalanine mimic of (L-tyrosine 04-sulfale)-63. Helv Chim Acta 1994; 77: 679-84.
9. Fenton JW II, Ofosu FA, Moon DG, Maraganore JM. Thrombin structure and function: why thrombin is the primary target for antithrombotics. Blood Coagulation Fibrinolysis 1991; 2: 69-75.
10. Kaiser B, Hauptmann J. Pharmacology of synthetic thrombin inhibitors of the tripeptide type. Cardiovasc Drug Rev 1992; 10: 71-87.
11. Lefkovits J, Topol FJ. Direct thrombin inhibitors in cardiovascular medicine. Circulation 1994; 90: 1522-36.
12. Markwardt F. Hirudin: the promising antithrombotic. Cardiovasc Drug Rev 1992; 10: 211-32.
13. Witting JI, Bourdon P, Brezniak DV, Maraganore JM, Fenton JW. Thrombin-specific inhibition by and slow cleavage of hirulog-1. Biochem J 1992; 283: 737-43.
14. Lidon R-M, Théroux P, Lesperance J, Adelman B, Bonan R, Duval D, Levesque J. A pilot, early angiographic patency study using a direct thrombin inhibitor as adjunctive therapy to streptokinase in acute myocardial infarction. Circulation 1994; 89: 1567-72.
15. Bittl JA, Strony J, Blinker JA, Ahmed WH, Meckel CR, Chatman BR, Maraganore J, Deutsch E, Adelman B. Treatment with bivaluridin (hirulog) as compared with heparin during coronary angioplasty for unstable or postinfarction angina. N Engl J Med 1995; 333: 764-9.
16. Lombardi A, Nastri F, Galdiero S, Delia Morte R, Staiano N, Pedone C, Pavone V. Rational design of enzymatically resistant, peptide based, multisite directed, α-thrombin inhibitors. American Peptide Symposium, Columbus (Ohio, USA), June 18-23, 1995; abstract n° P930.
17. Rick W. Trypsin. In Methods in Enzymatic Analysis. Bergmeyer HU ed.: Academic Press, I edition; 1963; 807-18.
18. Lowry OH, Rosebrough NJ, Farr AL, Randall LJ. Protein measurements with the Folin phenol reagent. J Biol Chem 1951; 193: 265-75.
19. Schumacher WA, Steinbacher TE, Heran CL, Seiler SM, Michel IM, Ogletree ML. Comparison of thrombin active site and exosite inhibitors and heparin in experimental models of arterial and venous thrombosis and bleeding. J Pharmacol Exp Ther 1993; 267: 1237-42.
20. Kelly AB, Maraganore JM, Bourdon P, Hanson SR, Harker LA. Antithrombotic effects of synthetic peptides targeting various functional domains of thrombin. Proc Natl Acad Sci USA. 1992; 89: 6040-4.
21. Kline T, Hammond C, Bourdon P, Maraganore JM. Hirulog peptides with scissile bond replacements resistant to thrombin cleavage. Biochem Biophys Res Commun 1991; 177: 1049-1055.
22. Cappiello M, Vilardo PG, Lippi A, Criscuoli M, Del Corso A, Mura U. Kinetics of human thrombin inhibition by two novel peptide inhibitors (Hirunorm IV and Hirunorm V). Biochem Pharmacol. In press.
23. Bichler J, Baynes JW, Thorpe SR. Catabolism of hirudin and thrombinhirudin complexes in the rat. Biochem J 1993; 296: 771-6.
24. Nowak G, Bucha E, Goock T, Thieler H, Markwardt F. Pharmacology of r-hirudin in renal impairment. Thromb Res 1992; 66: 707-15.
25. Antman EM. Hirudin in acute myocardial infarction. Safety report from the Thrombolysis and Thrombin Inhibition in Myocardial Infarction (TIMI) 9A trial. Circulation 1994; 90: 1624-30.
26. Fox I, Dawson A, Loynds P, Eisner J, Findlen K, Levin E, Hanson D, Mant T, Wagner J, Maraganore J. Anticoagulant activity of hirulog™, a direct thrombin inhibitor, in humans. Thromb Haemost 1993; 69: 157-63.
27. Agnelli G, Renga C, Weitz JL, Nenci GG, Hirsh J. Sustained antithrombotic activity of hirudin after its plasma clearance: comparison with heparin. Blood 1992; 80: 960-5.
28. Romisch J, Stöhr H-A, Stauß H, Koschinsky R, Stüber W, Paques E-P. Inhibition of in vitro dot growth by r-hirudin is more effective and longer sustained than by an analogous peptide. Thromb Haemost 1994; 71: 320-4.
29. Maraganore J. M. Hirudin and hirulog; advances in antithrombotic therapy. Perspectives in Drug Discovery and Design 1991; 1: 461-78.
30. Markwardt F. The development of hirudin as an antithrombotic drug. Thromb Res 1994; 74: 1-23.
31. Close P, Bichler J, Kerry R, Ekman S, Bueller HR, Kienast J, Marbel GA, Schramm W, Verstraete M. Weak allergenicity of recombinant hirudin CGP 39393 (REVASC) in immunocompetent volunteers. Coronary Artery Disease 1994; 5: 943-9.
32. Klocking H-P. Toxicology of hirudin. Semin Thromb Haemost 1991; 17: 126-9.